Dyschromia in Skin of Color

April 2014 | Volume 13 | Issue 4 | Original Article | 401 | Copyright © April 2014


Stephanie J. Kang DO,a Scott A. Davis MA,a Steven R. Feldman MD PhD,a,b,c and Amy J. McMichael MDa

aCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC
bCenter for Dermatology Research, Department of Pathology Wake Forest School of Medicine, Winston-Salem, NC
cCenter for Dermatology Research, Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC

Intendis. Dr. McMichael has received honoraria from Proctor and Gamble and Gunthy Renker. She has received grants from Galderma and other financial benefits from Intendis. Dr. Kang and Mr. Davis have no conflicts to disclose.

REFERENCES

  1. Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, Mc-Michael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11(4):466-473.
  2. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28(2):77-85.
  3. Makino ET, Herndon JH, Sigler ML, Gotz V, Garruto J, Mehta RC. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone. J Drugs Dermatol. 2012;11(12):1478-1482.
  4. Salem A, Gamil H, Ramadan A, Harras M, Amer A. Melasma: treatment evaluation. J Cosmet Laser Ther. 2009;11(3):146-150.
  5. Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg 2012;38(7 Pt 1):971-984.
  6. Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic Acid skin care regimen. J Drugs Dermatol. 2013;12(1):45-50.
  7. Cestari T, Arellano I, Hexsel D, Ortonne JP. Melasma in Latin America: options for therapy and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(7):760-772.
  8. Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol. 2010;22(4):373-378.
  9. Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs. 2004;16(5):401-406.
  10. U.S.Census Bureau. Monthly Estimates of the United States Population: April 1, 1980 to July 1, 1999.http://www census gov/population/estimates/nation/intfile1-1 txt 2001. AccessedJanuary 31, 2013.
  11. Kim WS. Efficacy and safety of a new superficial chemical peel using alpha-hydroxy acid, vitamin C and oxygen for melasma. J Cosmet Laser Ther. 2013;15(1):21-24.
  12. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65(4):689-697.
  13. Tan KL, Kurniawati C, Gold MH. Low risk of postinflammatory hyperpigmentation in skin types 4 and 5 after treatment with fractional CO2 laser device. J Drugs Dermatol. 2008;7(8):774-777.
  14. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett. 2004;9(6):1-3.
  15. Taylor SC. Enhancing the care and treatment of skin of color, part 1: The broad scope of pigmentary disorders. Cutis. 2005;76(4):249-255.
  16. Konda S, Geria AN, Halder RM. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 2012;31(2):133-139.
  17. Stratigos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5(3):161-168.
  18. Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther. 2004;17(2):196-205.
  19. Battle EF, Jr., Soden CE, Jr. The use of lasers in darker skin types. Semin Cutan Med Surg. 2009;28(2):130-140.
  20. Shah S, Alster TS. Laser treatment of dark skin: an updated review. Am J Clin Dermatol. 2010;11(6):389-397.
  21. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048-1065.
  22. Woolery-Lloyd H, Kammer JN. Treatment of hyperpigmentation. Semin Cutan Med Surg. 2011;30(3):171-175.
  23. Ortonne JP. [Normal and abnormal skin color]. Ann Dermatol Venereol. 2012;139 Suppl 3:S73-7. doi: 10.1016/S0151-9638(12)70114-X.):-X.
  24. Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol. 2008;84(3):539-549.
  25. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg. 1997;23(3):171-174.
  26. Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17(2):184-195.
  27. Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(1 Suppl):15-20.
  28. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74(6):362-368.
  29. Taylor SC, Torok H, Jones T et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67-72.
  30. Cayce KA, Feldman SR, McMichael AJ. Hyperpigmentation: a review of common treatment options. J Drugs Dermatol. 2004;3(6):668-673.
  31. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
  32. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308-313.
  33. Badreshia-Bansal S, Draelos ZD. Insight into skin lightening cosmeceuticals for women of color. J Drugs Dermatol. 2007;6(1):32-39.
  34. Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. J Cutan Aesthet Surg. 2012;5(4):247-253.

AUTHOR CORRESPONDENCE

Steven R. Feldman MD PhDsfeldman@wakehealth.edu
Close Menu